Renal denervation for hypertension
GSR real-world registry
With more than 3,000 patients enrolled, the Global SYMPLICITY Registry (GSR) is the largest renal denervation (RDN) data set in the world.
Unmatched real-world data
The Global SYMPLICITY Registry has demonstrated the safety and efficacy of the Symplicity™ blood pressure procedure in a variety of patients representative of daily clinical practice, making it a vital source of insights for patient selection. Significant blood pressure reductions were sustained out to three years in both office and 24-hour blood pressure (BP) measures.1–4
Sustained blood pressure reductions
Only the Symplicity™ RDN system has demonstrated sustained BP reductions through three years in real-world patients.2,3
18
mmHg
reduction in OSBP real-world patients at three years with the Symplicity Spyral™ catheter,
n = 2674
Global RDN insights
Prof. Markus Schlaich discusses Global SYMPLICITY Registry data for patients with resistant hypertension.
Excellent safety profile
The Global SYMPLICITY Registry study showed stable kidney function at three-year follow-up.1
Stable kidney function in real-world patients1
Real-world results
Significant BP reductions across high-risk subgroups
at three years in GSR
Advancing the study of long-term results
GSR DEFINE is a prospective, multicenter, single-arm, non-interventional and open-label registry that will document the long-term safety and efficacy of the Symplicity™ blood pressure procedure.
- 5,000 patients to be enrolled§
- 300+ sites worldwide
- One to five years of follow-up
Learn about the procedure
The Symplicity™ blood pressure procedure is changing how patients with hypertension can reduce their blood pressure.
Multiple RCTs
The Symplicity procedure has demonstrated signifcant and safe blood pressure reductions in randomized controlled trials.
Take action on hypertension
Gain access to resources to introduce the Symplicity™ blood pressure procedure to your community successfully.
Find education resources
Discover a wide range of educational content about the Symplicity™ blood pressure procedure, from links to third party education sites to recorded sessions from global RDN experts.
† Resistant hypertension defined as OSBP > 150 mmHg, ≥ 3 antihypertensive medications.
‡ CKD defined as eGFR < 60 ml/min/1.73 m2.
§ 2,000 incremental patients to the Global SYMPLICITY Registry.
1. Schlaich M, et al. Long-term safety and efficacy of renal denervation with the Symplicity Spyral™ catheter in the Global SYMPLICITY Registry. Presented at American Society of Nephrology Kidney Week, San Diego, CA. 2021.
2. Mahfoud F, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. EuroPCR 2023.
3. Mahfoud F, Mancia G, Schmieder RE, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the Global SYMPLICITY Registry DEFINE. Hypertension. 2023;80(8):1759–1770. doi: 10.1161/HYPERTENSIONAHA.123.21283.
4. Medtronic data on file. Global SYMPLICITY Registry clinical data snap, March 2023.
5. Mahfoud F, Mancia G, Schmieder R, et al. Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol. 2020;75(23):2879–2888. doi: 10.1016/j.jacc.2020.04.036.
6. Mahfoud F, et al. Blood pressure reduction after catheter-based renal denervation in patients with cardiovascular disease in the Global SYMPLICITY Registry. ESH 2022.
7. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451. doi: 10.1016/S0140-6736(20)30554-7.
8. Kandzari DE, Townsend RR, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.